Drugs Made In America Acquisition Corp. Price & Performance (DMAAU)

Bright Green Corporation has proposed a comprehensive restructuring plan involving a $3.5 billion investment in DEA and FDA-compliant facilities. The initiative aims to establish a U.S.-based supply chain for controlled substances, creating thousands of jobs and addressing a $100 billion market for prescription drugs.1

Better Choice Company is set to finalize its acquisition of SRx Health Solutions following a 93% shareholder approval. The deal, seen as a strategic move in the resilient pet health sector, is expected to enhance market reach and operational synergies while strengthening its competitive position.2

Eli Lilly plans to invest over $50 billion in U.S. pharmaceutical manufacturing by constructing four new facilities in 2025. This expansion is expected to create 13,000 jobs and boost economic growth, marking the largest domestic investment of its kind in the industry’s history.3